

Chair WG Clinical Translation and Social Impact

INTENTION AND TENTATIVE PROGRAMME FOR THE NEXT 2 YEARS

I have been active as Chair in WG Clinical Translation and Social Impact in the last years, supported by vice-chair Dr. Maria de la Fuente Freire. My Institution has been one of the Founder Member of ETPN therefore I joined the ETPN community from many years for all nanomedicine activities and projects and it has been a pleasure to be part of this community.

My application is reflecting the common vision and goals of the "Raymond Schiffelers team". The vision of our list, written in collaboration, is that we maintain to be recognized as the think tank and ambassador of the nanomedicine community and that we can be the broker for our members to the EC programs. An important element of the ETPN is keeping our members' research activities sustainable through the support of funding instruments for R&D&I projects in the field of nanomedicine and towards cross-KET solutions in healthcare. The main objectives of our activity will be:

- 1) take a leading position in the HealthTech4EU Alliance as this offers a good critical mass to influence EC strategic programming
- 2) support for nanomedicine entrepreneurs towards clinical and industrial implementation and show that nanomedicine can change patients' lives
- 3) secure ETPN funding with increased income from membership fees to keep ETPN sustainable and an attractive consortium partner

For the next two years, I propose to continue the work that I started with the Ruth Schimd board, in particular the vision that the ETPN strives to address unmet healthcare needs with innovative nanotechnology-based solutions for the benefit of patients. The pandemic COVID-19 situation affected also our WG activity, since me and my vice-chair work in hospitals. However we successfully are collaborating with other WGs to create an updated database and an interactive map of nano-related clinical trials that will be inserted in our website, in order to help the ETPN members finding new partners for collaboration in EU projects.

Our WG also prepared a new survey on unmet clinical needs to be shared, in the next period, between our members and also several clinicians of our hospitals networks.

The "Clinical Translation and Social Impact" working group (WG) will contribute by supporting the board in the networking activities and by proposing new attractive online tools and contents to ETPN members.

The idea of this WG is to align with the HORIZON EUROPE vision and the new funding and health landscape, establishing an impact-focused, mission-oriented approach (disease oriented). Listen to doctors:

"nanomedicine is a matter of medicine more than of nanotechnology".

I will select as vice-Chair Dr. Maria de la Fuente Freire (PI of Nano-Oncology Unit, IDIS, SERGAS, Santiago de Compostela Hospital, Spain) with a complementary expertise with the WG Chair. Dr. de la Fuente is expert on development and biological evaluation of nanotherapeutics in cancer.

The WG Clinical Translation and Social Impact will plan to complete some activities started in the previous 2 years but that suffered slow down due to pandemic situation and to start new activities.

The main goals are described in this tentative plan for Clinical Translation and Social Impact WG for the next 2 years.

- Complete and upload an updated version of clinical trials centers and increasing the networking with these clinical trials centers, useful also for the last phases in the TAB process.
- Share the updated version of unmet clinical needs inviting the clinicians from our hospitals networks and ETPN members.

- Promote and support the research projects that fit with the unmet clinical needs (pointed out by physicians, patients and social challenges) with a clear direction. Support a mentoring activity pre-TAB for the clinical research project at TRL 3/4, improving the interactions with the others WGs.
- Promote thematic webinar or similar in collaboration with other WGs to stimulate new possible members.
- Increase visibility in other clinical-related forums and attract clinical associations for membership.
- Maintain and where possible to increase the collaboration with the local Health Agencies or Government to be involved in different processes such as Public Procurement of Innovative solutions (PPI)
- Establish contact with patient's associations.
- Create documents stating the social impact of nanomedicine in healthcare (direct impact in survival, social-economy, etc, by resolving unmet clinical needs.

Table 1: Tentative plan for Clinical Translation and Social Impact WG for the next 2 years

Goal	Action	Sub-action
Updated version of nano-clinical trials centers	Complete the <u>updated version of clinical trials centers</u> (created in the last months) in collaboration with other WGs and increase the networking with these clinical trials centers	The clinical trials centers will be involved in ETPN activity like participation in EU projects
Updated version of unmet clinical needs	Share the <u>updated version of unmet clinical needs</u> inviting the clinicians to answer a survey on ETPN website.	Organize interview with expert clinicians nano-oriented
Thematic webinar to increase visibility	Promote <u>thematic webinar</u> or similar in collaboration with other WGs	Increase visibility in other clinical-related forums and attract clinical associations for membership
Collaboration with the local Health Agencies or Government	Maintain and where possible to <u>increase the collaboration</u> with them.	To be involved in different processes such as Public Procurement of Innovative solutions (PPI)
Patient's associations	Establish <u>contact with patient's associations to better understand the needs</u> in order to ameliorate the quality of patient's life	Create a survey for patients care-givers
Social impact of Nanomedicine in healthcare	Create <u>documents stating</u> the social impact of nanomedicine in healthcare	Direct impact in survival, social-economy, etc, by resolving unmet clinical needs.
Mentoring activity pre-TAB	Promote and support the research projects that fit with the unmet clinical needs (pointed out by physicians, patients and social challenges) with a clear direction	The clinical research project at TRL 3/4 will be supported improving the interactions with the others WGs (nanotherapeutics, medical device, business)

Thanks for your support.
Sincerely
Marzia Bedoni